Integrative analysis of genome-wide DNA methylation and single-nucleotide polymorphism identified ACSM5 as a suppressor of lumbar ligamentum flavum hypertrophy

Table 1 Clinical data of patients in two groups

Item	Sequencing of genome-wide SNP and DNA methylation			Verification of genome-wide SNP and DNA methylation
Item	non-HLF (n = 5)	HLF (n = 5)	P value	non-HLF (n = 10)	HLF (n = 10)	P value
Age/years	58 ± 5	75 ± 5	5.80E-02	52 ± 5	69 ± 3	2.00E-02
LF thickness/cm	0.28 ± 0.01	0.52 ± 0.03	6.12E-05	0.31 ± 0.01	0.52 ± 0.02	6.29E-09
Gender	3F/2M	4F/1M		5F/5M	8F/2M
Lumbar level	L4/5	L4/5		L4/5	L4/5

Data are presented as the mean ± S.E.M.. P < 0.05 is considered to be significant. LF, ligamentum flavum. Non-HLF, LDD patients without ligamentum flavum hypertrophy (LF thickness ≤ 4 mm). HLF, LDD patients with ligamentum flavum hypertrophy (LF Thickness > 4 mm). F/M, female/male

ISSN: 1478-6362